RIGEL PHARMACEUTICALS INC (RIGL) Stock Price, Forecast & Analysis

NASDAQ:RIGL • US7665597024

34.74 USD
-0.97 (-2.72%)
At close: Feb 27, 2026
34.74 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM

RIGL Key Statistics, Chart & Performance

Key Statistics
Market Cap630.53M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Shares18.15M
Float17.69M
52 Week High52.24
52 Week Low15.5
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)6.17
PE5.63
Fwd PE8.99
Earnings (Next)03-02
IPO2000-11-29
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
RIGL short term performance overview.The bars show the price performance of RIGL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

RIGL long term performance overview.The bars show the price performance of RIGL in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of RIGL is 34.74 USD. In the past month the price decreased by -1.19%. In the past year, price increased by 50.65%.

RIGEL PHARMACEUTICALS INC / RIGL Daily stock chart

RIGL Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to RIGL. When comparing the yearly performance of all stocks, RIGL turns out to be only a medium performer in the overall market: it outperformed 64.62% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
RIGL Full Technical Analysis Report

RIGL Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to RIGL. RIGL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RIGL Full Fundamental Analysis Report

RIGL Financial Highlights

Over the last trailing twelve months RIGL reported a non-GAAP Earnings per Share(EPS) of 6.17. The EPS increased by 4307.14% compared to the year before.


Industry RankSector Rank
PM (TTM) 40.17%
ROA 46.72%
ROE 96.34%
Debt/Equity 0.25
Chartmill High Growth Momentum
EPS Q2Q%108.57%
Sales Q2Q%25.59%
EPS 1Y (TTM)4307.14%
Revenue 1Y (TTM)79.13%
RIGL financials

RIGL Forecast & Estimates

12 analysts have analysed RIGL and the average price target is 47.94 USD. This implies a price increase of 38% is expected in the next year compared to the current price of 34.74.

For the next year, analysts expect an EPS growth of 617.8% and a revenue growth 69.07% for RIGL


Analysts
Analysts80
Price Target47.94 (38%)
EPS Next Y617.8%
Revenue Next Year69.07%
RIGL Analyst EstimatesRIGL Analyst Ratings

RIGL Ownership

Ownership
Inst Owners85.11%
Ins Owners2.59%
Short Float %21.09%
Short Ratio8.25
RIGL Ownership

RIGL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.98397.113B
AMGN AMGEN INC17.23204.262B
GILD GILEAD SCIENCES INC16.7178.373B
VRTX VERTEX PHARMACEUTICALS INC24.37121.819B
REGN REGENERON PHARMACEUTICALS16.8381.488B
ALNY ALNYLAM PHARMACEUTICALS INC49.743.76B
INSM INSMED INC N/A31.99B
NTRA NATERA INC N/A30.068B
BIIB BIOGEN INC12.6127.594B
UTHR UNITED THERAPEUTICS CORP17.121.685B

About RIGL

Company Profile

RIGL logo image Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Company Info

RIGEL PHARMACEUTICALS INC

611 Gateway Boulevard, Suite 900

South San Francisco CALIFORNIA 94080 US

CEO: Raul R. Rodriguez

Employees: 163

RIGL Company Website

RIGL Investor Relations

Phone: 13025814070

RIGEL PHARMACEUTICALS INC / RIGL FAQ

What does RIGEL PHARMACEUTICALS INC do?

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.


What is the current price of RIGL stock?

The current stock price of RIGL is 34.74 USD. The price decreased by -2.72% in the last trading session.


What is the dividend status of RIGEL PHARMACEUTICALS INC?

RIGL does not pay a dividend.


What is the ChartMill technical and fundamental rating of RIGL stock?

RIGL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


Is RIGEL PHARMACEUTICALS INC (RIGL) expected to grow?

The Revenue of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 69.07% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the market cap for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a market capitalization of 630.53M USD. This makes RIGL a Small Cap stock.


Can you provide the ownership details for RIGL stock?

You can find the ownership structure of RIGEL PHARMACEUTICALS INC (RIGL) on the Ownership tab.